Tempest Therapeutics Net Loss History

TPST Stock  USD 2.29  0.13  6.02%   
Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. At -26.7 M, Tempest Therapeutics's Net Loss is down 4.76% compared to -25.5 M last year. All Reported Financials
 
Net Loss  
 First Reported
2010-12-31
 Previous Quarter
-25.5 M
 Current Value
-26.7 M
 Quarterly Volatility
6.4 M
Macro event markers
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Among Tempest Therapeutics' reported metrics, Net Loss provides a view into a specific part of the financial picture. The most recent reading gains meaning when set against the full distribution of past values.

Latest Tempest Therapeutics' Net Loss Growth Pattern

Net Loss for Tempest Therapeutics moved from -25.5 M to -26.7 M over the most recent period. The most recent value of -26.7 M sits within a slightly volatile historical range. The curvature of Tempest Therapeutics' Net Loss trend adds context beyond what the raw numbers convey.
Net Loss10 Years Trend
Slightly volatile
All figures are presented for informational review.
   Net Income Applicable To Common Shares   
       Timeline  

Net Loss Trend Statistics

Arithmetic Mean-19,310,776
Coefficient Of Variation-33.29
Mean Deviation 5,830,651
Median-14,365,000
Standard Deviation 6,428,538
Sample Variance41.3T
Range13.9M
R-Value-0.84
Mean Square Error12.8T
R-Squared 0.71
Significance 0.000022
Slope-1,071,918
Total Sum of Squares661.2T

Tempest Therapeutics Net Loss History

2026-26.7 M
2025-25.5 M
2021-28.3 M
2020-19.2 M

Methodology, Assumptions & Data Sources

Here is how Tempest Therapeutics's Net Loss has changed over time. Year-over-year changes are the easiest way to spot turning points.

The analytics block for Tempest Therapeutics relies on periodic company reporting and market reference feeds, with quality checks and normalization applied before rendering. Professional analyst research is incorporated when coverage is available. Timing can vary by data vendor. This section presents reference data and historical patterns only and does not constitute an investment recommendation or advice.

This content is curated and reviewed by:

Rifka Kats - Member of Macroaxis Editorial Board
Last reviewed on March 5th, 2026